Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have led to dramatic improvements in survival a subset of patients with non-small cell lung cancer (NSCLC); however, they have been shown to cause life-threatening toxicity such as immune checkpoint inhibitor-related pneumonitis (CIP). Our previous studies have shown that chronic obstructive pulmonary disease (COPD) and circulating cytokines are associated with clinical outcomes in NSCLC patients receiving ICIs. However, the relationship between these factors and the development of CIP is unclear. In this study, we retrospectively assessed NSCLC patients receiving ICIs to identify CIP risk factors.

Methods

This retrospective cohort study reviewed medical records of NSCLC patients receiving ICIs targeting programmed cell death 1

SUBMITTER: Chao Y 

PROVIDER: S-EPMC8902097 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature